LANDOVER, MD--(Marketwired - May 05, 2014) - The Epilepsy Foundation announced today that the 4th Biennial Epilepsy Pipeline Conference 2014, an initiative of the Epilepsy Therapy Project, will feature a stellar line up of therapeutic and medical device developers, clinical investigators and industry leaders presenting the latest epilepsy therapies in development. The conference will highlight the most pressing issues faced by the epilepsy community today including the evaluation of medical marijuana; how to accelerate epilepsy research innovation to the next stage; and the urgent unmet need for new therapies for the millions of people with epilepsy who are not receiving adequate seizure control. This year's conference will also feature the annual "Shark Tank " competition where new ideas arising from researchers and entrepreneurs are invited to compete for funding that will advance their inventive product concepts with the promise of improving the lives of people with epilepsy. The Epilepsy Pipeline Conference will be held on June 5-7, 2014, at the Hyatt Regency San Francisco.
Companies and organizations selected by the Epilepsy Foundation's prestigious Scientific and Business Advisory Boards to present their epilepsy products and programs in development include: Intellimedix, Asklepios BioPharmaceutical, AurimMed Pharma, BioCrea, EpaleX, Fluorinov Pharma, NeuroGate Therapeutics, NeuroGenomeX, INSYS Therapeutics, NeuroAdjuvants, University of South Florida, SciFluor Life Sciences, Sage Therapeutics, Cyberonics, Brain Sentinel, Epitel, Empatica, Smart Monitor, RTI International, Medtronic, NeuroSigma, UCLA, Visualase, Swedish Neuroscience Institute, Boston Children's Hospital, Ultragenyx Pharmaceutical, Alexza Pharmaceuticals, Convergence Pharmaceuticals, GW Pharmaceuticals, Insero Health, Marinus Pharmaceuticals, SK Life Science, UCB and Vertex Pharmaceuticals.
Pharmaceutical, biotechnology and device industry executives, investors, clinical scientists, technology transfer executives and the epilepsy community are invited to hear directly from leaders in the field and register to attend the 2014 Epilepsy Pipeline Conference at http://bit.ly/PipelineConference. All registrants are encouraged to take advantage of early bird registration rates through May 12, 2014.
"The Epilepsy Pipeline Conference is recognized as the scientific, industry and funding forum for those seeking support for new approaches that leverage both what we understand and are learning today about epilepsy and seizure conditions," said Philip M. Gattone, president and CEO of the Epilepsy Foundation. "We are taking a hands-on role in advocating, funding and urging all industry partners and innovators to accelerate their products through development and ultimately to people living with seizures."
Keynotes Address Therapeutic Innovation; Additional Program Highlights
Keynote addresses on the annual state of the epilepsy drug pipeline and the epilepsy device pipeline will be delivered by Jacqueline French, MD, Professor of Neurology, New York University and Robert Fisher, MD, PhD, Professor of Neurology, Director Stanford Comprehensive Epilepsy Program, respectively.
The conference will include perspective on epilepsy therapy development from the National Institute of Neurological Disorders and Stroke (NINDS) and the U.S. Food and Drug Administration (FDA). Other sessions will discuss grants, funding and investment in epilepsy and CNS research from sources including the government, non-profit organizations, crowdfunding and innovative investment firms such as Poliwogg.
This year's conference will also feature scientific poster and commercial exhibit sessions. Poster submissions and exhibitors are still being accepted. For more information, please visit http://bit.ly/PipelinePoster.
See the Epilepsy Shark Tank Finalists Compete
The third annual epilepsy "Shark Tank" competition will take place on the second day of the conference, June 6, 2014. Judged by a live audience, Shark Tank finalists will compete for grants totaling $200,000 to support new products, technology and therapeutics. Finalists include Roozbeh Ghaffari, PhD, Director, Advanced Technology Development at Mc10, Inc.; Sandra L. Helmers, MD, MPH, Professor of Neurology and Pediatrics, Emory University School of Medicine; Ahmed Helmy, Associate Professor, Computer and Information Science and Engineering Department, University of Florida; Oren Knopfmacher, PhD, Avails Medical, Inc.; Michel Lundell, M Object Oriented Software Engineering AB; Jon Davis, Inventor.
Day 3, Family Day
The third day of the conference, "Family Day," is designed for people with epilepsy, families and advocates; registration for this day is free of charge. The challenges of epilepsy, medical marijuana and dietary therapies are among the topics to be addressed. Attendance for the June 7 program has achieved capacity, and those still interested in participating may inquire about wait list status.
Epilepsy -- a medical condition characterized by recurring seizures -- can affect anyone, of any age, at any time. While it is estimated that one in 26 Americans will develop the seizure condition in their lifetime, current treatments for epilepsy do not work for more than three out of 10 children and adults diagnosed -- leaving many Americans with no or inadequate control over their daily seizures and with the risk of further injury or fatality.
About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with more than 48 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The mission of the Epilepsy Foundation is to stop seizures and sudden unexpected death in epilepsy (SUDEP), find a cure and overcome the challenges created by epilepsy through efforts including education, advocacy and research to accelerate ideas into therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit www.epilepsy.com.
The following files are available for download: